Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on the botulinum neurotoxins.

A Carruthers1, J Carruthers

  • 1Division of Dermatology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Skin Therapy Letter
|January 29, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal associations between individual changes in hormones, training motivation and physical performance in elite and non-elite trained men.

Biology of sport·2016
Same author

Translation of tobacco control programs in schools: findings from a rapid review of systematic reviews of implementation and dissemination interventions.

Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals·2014
Same author

Common problems in pediatric ophthalmology.

Canadian family physician Medecin de famille canadien·2011
Same author

The hydrolysis of the alkenyl group from enthanolamine-plasmalogen by oligodendroglial cell-enriched fractions.

Neurochemistry international·2010
Same author

Photoporation and cell transfection using a violet diode laser.

Optics express·2009
Same author

Botulinum toxin products overview.

Skin therapy letter·2008
Same journal

Exosomes in Dermatology.

Skin therapy letter·2026
Same journal

Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.

Skin therapy letter·2026
Same journal

Erratum to: Deuruxolitinib for Alopecia Areata.

Skin therapy letter·2026
Same journal

Advances in the Management of Hyperhidrosis.

Skin therapy letter·2026
Same journal

Topical Ruxolitinib for the Treatment of Hidradenitis Suppurativa.

Skin therapy letter·2026
Same journal

Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis.

Skin therapy letter·2026
See all related articles

Botulinum neurotoxins (BTX) are increasingly used for therapeutic purposes, with expanded FDA approvals for conditions like cervical dystonia and cosmetic applications. Improved formulations have reduced side effects and secondary resistance, enhancing patient outcomes.

Area of Science:

  • Neurology
  • Pharmacology
  • Cosmetic Science

Background:

  • Botulinum neurotoxins (BTX) are potent therapeutic agents with a growing range of clinical applications.
  • Current FDA-approved BTX products include BOTOX (BTX-A) and Myobloc (BTX-B).

Purpose of the Study:

  • To highlight the expanding clinical indications for botulinum neurotoxins.
  • To discuss the safety and efficacy of BTX therapies.
  • To address concerns regarding side effects and resistance.

Main Methods:

  • Review of clinical applications and regulatory approvals for BTX.
  • Analysis of factors influencing the incidence of secondary resistance to BTX.

Main Results:

  • BTX-A and BTX-B are approved for cervical dystonia treatment in the US.

Related Experiment Videos

  • BOTOX is approved in Canada for glabellar frown lines, with expected US FDA approval.
  • Reduced non-toxic protein in BOTOX has significantly decreased secondary resistance.

    • Conclusions:

    • The clinical use and marketing of BTX are expanding rapidly.
    • Increased clinical experience is mitigating concerns about BTX risks and side effects.
    • Formulation improvements have enhanced the long-term effectiveness of BTX therapies by reducing resistance.